GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
Genital herpes simplex virus (HSV) infections are frequently asymptomatic or undiagnosed, but more than half the US population is seropositive for HSV, and about one-fifth are positive for HSV-2.
Without revealing specific details, GSK announced that it is terminating the development of its investigational herpes ...
GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...
A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the ...
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...
GlobalData on MSN6d
GSK’s Phase I/II herpes simplex vaccine trial misses primary endpointGSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet its primary efficacy endpoint. The ...
GSK's HSV vaccine candidate fails mid-stage trial, will not progress to late-stage trial. No safety concerns observed.
LONDON, UK I 11, 2024 I GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary objective data analysis from the phase II part of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback